Clinical Trial Update: An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease [Phase 1, Phase 2]

View source ↗

Summary

An extension study assessed long-term efficacy and safety of BMN 190 in patients with CLN2 disease (a form of Batten disease), reporting results after Phase 1/2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Batten Disease
• Cln2 Disease
• Cln2 Disorder
• Jansky-bielschowsky Disease
• Late-infantile Neuronal Ceroid Lipofuscinosis Type

Drugs mentioned

• BMN 190

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Jansky-Bielschowsky Disease, Batten Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-08-24